Journal of vascular and interventional radiology : JVIR · 2026
Safety and Effectiveness of the Low-Profile Braided Occluder Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations: A Single-Center Retrospective Experience.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Valentine Roshan, Du Pisane Johannes L, Mohnasky Michael, Gad Sandra, Williams Baxter, Brown Benjamin, Mauro David M, Afrasiabi Ali, Gholami Bahareh, Smith Karen, Kasthuri Raj S, Kokabi Nima
Аннотация
PURPOSE: To evaluate the safety, technical success, and short-term clinical effectiveness of the low-profile braided occluder (LOBO) device for embolization of pulmonary arteriovenous malformations (PAVMs).
MATERIALS AND METHODS: A single-center retrospective study of 23 consecutive patients (mean, 42.3 [SD ± 19]; female, 82%) with PAVMs underwent transcatheter embolization using LOBO devices. Clinical effectiveness was defined as the absence of PAVM recanalization/persistence and ≥70% reduction in sac size on 6-month follow-up computed tomography (CT) angiography. Adverse events were also assessed following embolization.
RESULTS: Of the 23 patients treated, 87% had hereditary hemorrhagic telangiectasia. Fifty-nine feeding arteries were embolized using a single device per feeder (LOBO 3, n = 37; LOBO 5, n = 18; LOBO 7, n = 3; LOBO 9, n = 1) with no additional coils or other embolic devices required. Mean feeding artery diameter was 2.93 mm (SD ± 1.05). The mean fluoroscopy time was 29.19 minutes (SD ± 20; median, 24.9 minutes; range, 4.6-106.9 minutes), and mean radiation dose was 623.5 mGy (SD ± 598; median, 404 mGy; range, 18-3,135 mGy). Technical success was 100%, with no intraprocedural device maldeployment or migration. At imaging follow-up of approximately 6 months (mean. 251 days [SD ± 74.55]; median, 266 days; range, 154-474 days), there was no recanalization of treated arterial feeders and nopersistence or recanalization of the PAVM sac, hence, 100% clinical success. No device-related adverse events or major procedure-related adverse events were observed.
CONCLUSIONS: In this single-center experience, the LOBO device appears to be a safe and effective option for PAVM embolization, with promising short-term results.
MATERIALS AND METHODS: A single-center retrospective study of 23 consecutive patients (mean, 42.3 [SD ± 19]; female, 82%) with PAVMs underwent transcatheter embolization using LOBO devices. Clinical effectiveness was defined as the absence of PAVM recanalization/persistence and ≥70% reduction in sac size on 6-month follow-up computed tomography (CT) angiography. Adverse events were also assessed following embolization.
RESULTS: Of the 23 patients treated, 87% had hereditary hemorrhagic telangiectasia. Fifty-nine feeding arteries were embolized using a single device per feeder (LOBO 3, n = 37; LOBO 5, n = 18; LOBO 7, n = 3; LOBO 9, n = 1) with no additional coils or other embolic devices required. Mean feeding artery diameter was 2.93 mm (SD ± 1.05). The mean fluoroscopy time was 29.19 minutes (SD ± 20; median, 24.9 minutes; range, 4.6-106.9 minutes), and mean radiation dose was 623.5 mGy (SD ± 598; median, 404 mGy; range, 18-3,135 mGy). Technical success was 100%, with no intraprocedural device maldeployment or migration. At imaging follow-up of approximately 6 months (mean. 251 days [SD ± 74.55]; median, 266 days; range, 154-474 days), there was no recanalization of treated arterial feeders and nopersistence or recanalization of the PAVM sac, hence, 100% clinical success. No device-related adverse events or major procedure-related adverse events were observed.
CONCLUSIONS: In this single-center experience, the LOBO device appears to be a safe and effective option for PAVM embolization, with promising short-term results.